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Atelocollagen is a major animal protein that is used as a highly biocompatible biomaterial. To date, atelocollagen has been used
as an eﬀective drug delivery technology to sustain the release of antitumor proteins and to enhance the antitumor activity of
oligonucleotides in in vivo models. However, the biological eﬀects of this technology are not fully understood. In the present
study, we investigated the eﬀects of atelocollagen on endothelial paracellular barrier function. An atelocollagen formulation
containing oligonucleotides speciﬁcally increased the permeability of two types of endothelial cells, and the change was dependent
on the molecular size, structure of the oligonucleotides used and the concentrations of the oligonucleotide and atelocollagen in
the formulation. An immunohistochemical examination revealed that the formulation had eﬀects on the cellular skeleton and
intercellular structure although it did not aﬀect the expression of adherens junction or tight junction proteins. These changes were
induced through p38 MAP kinase signaling. It is important to elucidate the biological functions of atelocollagen in order to be
able to exploit its drug delivery properties.
1.Introduction
Collagen is a major connective tissue protein that plays an
important role in the extracellular matrix in animals. As
such, collagen possesses good biocompatibility with animal
body tissues [1]. Atelocollagen is a type of soluble colla-
gen produced from tropocollagen, the collagen molecule
that makes up collagen ﬁbrils, via the elimination of the
telopeptide moieties, which are considered to account for
most of collagen’s antigenicity [1, 2]. Thus, atelocollagen is
considered to have little immunogenicity, which makes it a
safe biomaterial [1]. In fact, it is widely used for implantable
medical and plastic surgical products [1].
Atelocollagen is also used as a drug delivery carrier.
Forexample,aminipelletatelocollagenformulationhasbeen
demonstrated to sustain the release and maintain stable
blood concentrations of protein drugs for more than 1
week [2]. Many kinds of protein drugs such as interferon-
α [3], interleukin-2 [4], nerve growth factor [5], and
bone morphogenetic protein [6], and so forth, have been
administeredusingthisdrugdeliverysystem,andinterferon-
α and interleukin-2 showed strong antitumor activities in
animal models when administered in this manner [3, 4]. In
the past decade, as well as being used as a solid substrate,
dissolved atelocollagen has been used as a drug delivery
vehicle for nucleic acid-based medicines for gene conver-
sion [7], inﬂammatory disease [8, 9], and tumor therapy.
Atelocollagen can be used to deliver most kinds of nucleic
acid-basedmedicinesincludingplasmidDNA[10],antisense
oligodeoxynucleotides (ODN) [11–13], short interference
RNA (siRNA) [14–20], and micro RNA (miRNA) [21–23]. It
isalsocapableofdeliveringoligonucleotidestosubcutaneous
xenografts and metastatic tumors after its local and/or
systemic administration.2 Journal of Drug Delivery
Many studies, including some involving in vivo tumor
models, have evidenced the contribution of atelocollagen to
the enhancement of drugs’ antitumor activities, and some of
them described the mechanisms. For example, nucleic acids
delivered by atelocollagen are protected against degradation
by host nucleases [8, 14, 24], and it has also been shown to
improve the delivery eﬃciency of oligonucleotides to tumors
[15, 16]. However, the biological functions of atelocollagen
and the mechanism by which it enhances delivery eﬃciency
are still not fully understood. It is essential to reveal the
biological characteristics of atelocollagen in order to be able
to fully exploit its drug delivery potential. While we were
studying the basic properties of atelocollagen, we discovered
anotherofitsfunctions:itincreasesendothelialpermeability.
Here, we describe the results of a study of the eﬀects of
atelocollagen on intercellular sealing function. We mea-
sured transendothelial electrical residence (TER) in order
to estimate intercellular barrier function and performed
an immunohistochemical examination to see whether any
cellular morphological changes were induced.
2.MaterialsandMethods
2.1. Atelocollagen, Oligonucleotides, and Formulations. Ate-
locollagen was supplied in aqueous form by Koken (Tokyo,
Japan). Rhodamine red-conjugated atelocollagen was pre-
pared in accordance with the manufacturer’s instructions
(FluoReporter Rhodamine Red-X Protein Labeling Kit; Life
technologies Japan, Tokyo, Japan).
The oligodeoxynucleotides (ODN) and double stranded
RNA (dsRNA) were synthesized by Eurogentec (Seraing,
Belgium). The sequences of the oligonucleotides are listed in
Table 1 [20, 25, 26].
Each atelocollagen-oligonucleotide formulation (AC for-
mulation) was prepared by gently mixing aqueous atelocol-
lagen with a solution containing a deﬁned concentration
of oligonucleotides. The ﬁnal oligonucleotide concentration
was usually 5μM and that of atelocollagen was 0.1%w/v
unless otherwise stated in the text, tables, and/or ﬁgures.
2.2. Transendothelial Electrical Resistance (TER) Measure-
ment. Normal human dermal microvascular endothelial
cells (HMVEC) were purchased from EIDIA (Tokyo, Japan).
These cells were cultured in EGM (Endothelial Growth
Media; EIDIA, Tokyo, Japan) until they reached conﬂuence
on 12mm transwell ﬁlters with a 0.4μm pore size (Corning
Glass Works; Corning Japan, Tokyo, Japan) coated with rat
tail collagen. Porcine brain microvascular endothelial cells
(BMVEC) were puriﬁed and maintained according to the
method described in a previous study [27].
TER was determined using an EVOM voltohmmeter and
an ENDOHM-12 chamber (World Precision Instruments,
Sarasota, FL) at 37◦C[ 28]. Cell growth was monitored by
measuring TER. Once stable intercellular seals had formed;
that is, at conﬂuence, the medium in the inner chamber was
exchanged for 400 microliters of culture medium containing
30%v/vofAC formulation.TERwassubsequentlymeasured
in duplicate every 30min.
2.3. Measurement of Paracellular Flux. HMVEC cells were
also used for the determination of paracellular ﬂux. One
hour after treatment with the AC formulation, which was
performed as described in Section 2.2, 100μL of 0.36%w/v
Texas red-conjugated dextran (MW: 40kDa; Life Tech-
nologies Japan, Tokyo, Japan) were added to the inner
chamber. One hour later, the dextran concentration of the
medium in the outer chamber was analyzed by measuring its
ﬂuorescence.
To investigate the enhancement of paracellular transport
by atelocollagen, solute transportation was compared among
the AC formulation, bovine serum albumin, and dextran.
Once stable intercellular seals had formed, the medium in
the inner chamber was exchanged for 400 microliters of
culture medium containing 30%v/v of the AC formulation,
which had been produced using 0.1 or 0.3%w/v rhodamine
red-conjugated atelocollagen (i.e., approximately 0.03 or
0.1%w/v atelocollagen was added; molecular weight (MW):
300kDa); 0.1%w/v of ﬂuorescein conjugated dextran (MW:
70kDa; Life Technologies Japan, Tokyo, Japan); 0.1%w/v of
Alexa Fluor 594 conjugated bovine serum albumin (BSA;
MW: 66kDa; Life Technologies Japan, Tokyo, Japan). The
solute concentrations of the outer chambers were analyzed
by measuring their ﬂuorescence at 1 and 2 hours after the
medium exchange.
2.4. Immunohistochemistry. After treatment for 1hr with the
AC formulation, oligonucleotide alone, atelocollagen alone,
or phosphate-buﬀered saline (PBS) as a control, HMVEC
cells were ﬁxed with 1% paraformaldehyde for 10min and
then treated with 0.2% Triton X-100 for 10min. After
preincubation with 5% skimmed milk, they were incubated
for1hratroomtemperaturewithrabbitormouseantibodies
against vascular endothelial (VE)-cadherin (BD Biosciences,
SanDiego,CA),zonulaoccludens-1(ZO-1)(ZymedLabora-
tories, San Francisco, CA), claudin-5 (Zymed Laboratories,
San Francisco, CA), and α-tubulin (Amersham, Poole, UK).
Then, the samples were incubated for 1hr with appropriate
secondary antibodies labeled with Alexa Fluor-488 or Alexa
Fluor-596 (Life Technologies Japan, Tokyo, Japan). Actin
ﬁlaments were labeled with Alexa Fluor-546 phalloidin (Life
TechnologiesJapan,Tokyo,Japan).Thecellswerethoroughly
rinsed with PBS between each procedure. The expression of
each protein was examined using a laser scanning confocal
microscope (MRC 1024; Bio-Rad, Hercules, CA).
2.5. Western Immunoblotting. Western blotting was per-
formed according to the method described in a previous
report [29]. For Western blotting of the total cell lysates, the
dishes were washed with PBS, and then 300μLo fs a m p l e
buﬀer (1mM NaHCO3 and 2mM phenylmethylsulfonyl
ﬂuoride) was added to 60mm culture dishes. The cells
were scraped and collected in microcentrifuge tubes and
then sonicated for 10sec. The protein concentrations of
the samples were determined using a BCA (bicinchoninic
acid) protein assay reagent kit (Pierce Chemical, Rockford,
IL). For each sample, aliquots of protein (15μg per lane)
were separated by electrophoresis in 4/20% sodium dodecylJournal of Drug Delivery 3
Table 1: Eﬀects of formulation composition on relative TER (%).
(a) Eﬀects of oligonucleotide type.
Oligonucleotides Atelocollagen
concentration TER (%)
Type, sequences Reference Concentration
Blank control 100.0
Phosphorothioate
Oligodeoxynucleotide 5 -TGCATCCCCCAGGCCACCAT-3  25 5μM 92.7
Atelocollagen alone 0.1% 88.1
Phosphorothioate
Oligodeoxynucleotide 5 -TGCATCCCCCAGGCCACCAT-3  25 5μM 0.1% 45.7
Phosphodiester
Oligodeoxynucleotide 5 -TGCATCCCCCAGGCCACCAT-3  5μM 0.1% 81.4
Double stranded small RNA 5 -UGCAUCCCCCAGGCCACCAUdTdT-3 
and complemental sequence 20 5μM 0.1% 57.9
(b) Eﬀects of ODN sequence on TER (%).
Oligonucleotides Atelocollagen
Name Sequence Reference Concentration 0% 0.1%
TER (%)
Blank control 100 —
ODN-(1) 5 -TGCATCCCCCAGGCCACCAT-3  25 5μM 100 58
ODN-(2) 5 -TCGCATCGACCCGCCCACTA-3  25 5μM 100 54
ODN-(3) 5 -GCTGATTAGAGAGAGGTCCC-3  26 5μM 100 50
ODN-(4) 5 -CCCTGGAGAGAGATTAGTCG-3  5μM9 6 6 5
(c) Eﬀects of ODN length on TER (%).
Oligonucleotides Atelocollagen
Sequence Concentration 0% 0.1%
Examination (1) TER (%)
Blank control — 94.6 —
Atelocollagen alone — — 94.6
ODN 10-mer (5 -TGCATCCCCC-3 )5 μM 106.3 102.8
ODN 15-mer (5 -TGCATCCCCCAGGCC-3 )5 μM 94.1 47.1
ODN 20-mer (5 -TGCATCCCCCAGGCCACCAT-3 ;R e f .[ 25]) 5μM 107.1 50.0
ODN 30-mer (20-mer ODN + 10-mer ODN) 5μM 102.9 43.8
Examination (2) TER (%)
Blank control — 87.4 —
Atelocollagen alone — — 83.3
ODN 20-mer (5 -TGCATCCCCCAGGCCACCAT-3 ;R e f .[ 25]) 5μM 91.7 51.4
ODN 30-mer (20-mer ODN + 10-mer ODN) 5μM 83.3 26.5
ODN 50-mer (20-mer ODN × 2 + 10-mer ODN) 5μM 85.7 35.3
ODN 100-mer (20-mer ODN × 5) 5μM 82.4 50.0
(d) Eﬀects of the concentrations of ODN and atelocollagen on TER (%).
ODN concentration Atelocollagen
0% 0.003% 0.03% 0.1%
TER (%)
Blank control 94.6
0.5μM 100.0 77.8
5μM 102.8 43.7
50μM 102.9 50.8
500μM 91.7 28.5
TER (%)
Atelocollagen alone 100.0
5μM 94.9 98.1 54.9 52.0
ODN sequence: 5 -TGCATCCCCCAGGCCACCAT-3 .
TER(%): relative value at 1.5 hrs compared to the value observed at the start of the experiment.4 Journal of Drug Delivery
sulfate polyacrylamide gels (Cosmo Bio, Tokyo, Japan)
(SDS PAGE). After being electrophoretically transferred to
nitrocellulose membranes (Immobilon; Millipore, Billerica,
MA), the membranes were saturated with blocking buﬀer
(trisbuﬀered saline [TBS] supplemented with 0.1% tween
20 and 4% skimmed milk) for 30min at room temper-
ature and incubated with antiactin, anti-ZO-1, anti-VE-
cadherin (BD Biosciences, San Diego, CA), anticlaudin-5
(ZymedLaboratories,SanFrancisco,CA),anti-p38mitogen-
activated protein kinase (MAP Kinase or MAPK) (Santa
Cruz Biotechnology, Santa Cruz, CA), antiphospho-p38
MAPK (Cell Signaling, Beverly, MA), anti-p42/44 MAPK
(Promega, Madison, WI), antiphospho-p42/44 MAPK (Cell
Signaling, Beverly, MA), anti-Rho-A, and anti-cdc42 (Santa
Cruz Biotechnology, Santa Cruz, CA) antibodies (1:1000)
for 1h at room temperature. The membranes were then
incubated with horseradish peroxidase-conjugated anti-
rabbit or mouse IgG (Dako A/S, Copenhagen, Denmark) at
room temperature for 1h. The immunoreactive bands were
detected using an ECL Western blotting analysis system (GE
Healthcare, Little Chalfont, UK).
3. Results
3.1.ModiﬁcationofEndothelialSealingFunction. Paracellular
ﬂux is dependent on the function of tight junctions [30, 31].
We assessed the eﬀects of an AC formulation on the TER
of HMVEC to evaluate their tight junction function. As
shown in Figure 1 and Table 1(a), the ODN containing AC
formulation caused a time-dependent reduction in TER,
w h i l eT E Rw a sh a r d l ya ﬀected by treatment with ODN or
atelocollagen alone. As for the type of oligonucleotide in
the formulation, phosphorothioate ODN produced a more
signiﬁcant reduction in TER than phosphodiester ODN,
which only produced slight alterations. A change in the TER
value was also induced by treatment with small dsRNA.
Various formulations containing diﬀerent ratios of ODN
and atelocollagen were examined in order to understand
which parameters have the greatest eﬀect on the change
in TER. As a result, we found that the TER change was
dependent on the size of the ODN and the composition of
the formulation, but not the ODN sequence, as shown in
Tables 1(b), 1(c), and 1(d). Speciﬁcally, ODN composed of
15 or more bases were eﬀective and those containing around
30 bases were the most eﬀective, but 10-base-long ODN were
not eﬀective. The change in tight junction function was also
dependent on the concentrations of ODN and atelocollagen
in the formulation.
To verify that the AC formulation increased paracellular
ﬂux, the amount of Texas red-labeled dextran (molecular
weight: 40kD) transported across an endothelial cell layer
was examined. As shown in Figure 2(a), dextran transport
was increased approximately twofold in the cell cultures
incubated with the AC formulation.
Next, the paracellular transport of atelocollagen was
analyzed and compared with those of BSA and dextran.
Neither BSA nor dextran aﬀected the TER value of the cells.
Only very small amounts of BSA and dextran penetrated the
cell sheet during the 2-hour study period; on the other hand,
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Figure 1: Time-dependent reduction of TER after treatment with
diﬀerent types of oligonucleic acids in combination with atelo-
collagen. HMVEC cells were treated with 5μM of oligonucleic
acids with or without 0.1% atelocollagen. sODN: phosphoroth-
ioate oligodeoxynucleotide, oODN: phosphodiester oligodeoxynu-
cleotide, dsRNA: small double stranded RNA. The sequences of the
ODN are described in Table 1(a).
much more atelocollagen passed through, even though the
molecular weight of atelocollagen is 4-5 times higher than
those of BSA and dextran (Figure 2(b)).
An examination using BMVEC [27]w a sp e r f o r m e dt o
determine whether the eﬀect of the AC formulation was
speciﬁc to HMVEC. As a result, we found that the TER value
of the BMVEC was also reduced by the AC formulation (and
only the AC formulation), as shown in Figure 3.B M V E C
forms the blood-brain barrier (BBB), where intercellular
sealing function is strictly maintained. These results showed
that the AC formulation is able to aﬀect the paracellular ﬂux
of endothelial barriers.
3.2. Eﬀects on Cell Morphology. It is well known that in-
creased endothelial permeability is associated with impaired
intercellular contact [32–35]. We carried out an immuno-
histochemical analysis of the cells treated with the AC
formulation to clarify how their intercellular sealing was
aﬀected. As shown in Figure 4(a), treatment with the AC
formulation markedly reduced the degree of intercellular
contact, as shown by intercellular gap formation, actin
stress ﬁber formation, cellular contraction, and a lack of
VE-cadherin. Adequate expression of claudin-5, one of the
key components of the endothelial barrier, was noted at
the cell periphery. However, ZO-1 protein expression was
absent from the intercellular gaps. On the contrary, Western
blotting revealed that treatment with the AC formulation
did not aﬀect the expression of these proteins (Figure 4(b)).
Although the TER value remained low as long as the AC
formulation was present in the culture medium, the treat-
mentdidnotcausetoxicity.Thecellssurvivedwellforatleast
24hrs, and both the TER and morphology of the cells could
be recovered by removing the formulation (data not shown).Journal of Drug Delivery 5
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Figure 2: Eﬀects of the AC formulation on endothelial paracellular ﬂux. (a) Increase in dextran permeation induced by the AC formulation.
Onehouraftertheadditionofoligodeoxynucleotides(ODN),atelocollagen(AC),ortheACformulation(AC+ODN)totheinnerchambers,
Texas red-conjugated dextran (MW: 40,000) was added to the inner chambers. One hour later, the dextran concentration of the medium in
the outer chambers was determined. (b) Enhanced paracellular transport of atelocollagen. 0.1%w/v of Alexa Fluor 594 conjugated bovine
serum albumin (BSA; MW: 66kDa), 0.1%w/v of ﬂuorescein conjugated dextran (dextran; MW: 70kDa), or rhodamine red-conjugated
atelocollagen (0.03%w/v: atelocollagen (Low); 0.1%w/v: atelocollagen (High); MW of atelocollagen: 300kDa) with 5μMo fO D Nw a s
added to the inner chambers. The solute concentrations of the outer chambers were analyzed by measuring their ﬂuorescence at 1 and 2
hours after the start of the experiment. TER at 2 hours is represented as a percentage value compared to that observed at the start of the
experiment.
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Figure 3:EﬀectsoftheACformulationontheTERofBMVEC.The
bar represents TER as a percentage compared to the value observed
at the start of the experiment. TER was determined at 1 and 2
hours after treatment with ODN alone (ODN), atelocollagen alone
(atelocollagen), the AC formulation (atelocollagen + ODN).
No such morphological changes were induced by treatment
with ODN or atelocollagen alone (Figure 4(a)).
Microtubules play an important role in regulating actin
formation and hence, endothelial barrier function [36, 37].
We also histopathologically examined the shape of the
microtubules. As shown in Figure 5, α-tubulin formed a ﬁne
network in the blank control. However, treatment with the
AC formulation caused the peripheral ﬁne structure of the
α-tubulin network to be lost.
3.3. Activation of Signal Transduction-Related Molecules.
Many studies have shown that increased endothelial perme-
ability and impaired intercellular contact can be induced by
signal transduction, mainly that of Rho A [32, 38] and p38
MAP kinase [36, 39–42]. Thus, we investigated the eﬀects
of the AC formulation on signal transduction. As a result,
no diﬀerences were found in the expression levels of Rho-
A, Cdc42, or P42/44 MAP kinases or their phosphorylated
forms. Regarding p38 MAP kinase, although no changes
were noted among the control, oligonucleotide alone, or
atelocollagen alone groups, the levels of phosphorylated p38
MAP kinase were markedly increased in the cells treated
with the AC formulation (Figure 6), which indicates that6 Journal of Drug Delivery
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Figure 4: Eﬀects of atelocollagen combined with ODN on intercellular formation. (a) Images of actin, VE-cadherin with actin, ZO-1, and
claudin-5 in the endothelial cells of the blank control (upper panels) and the cells treated with the AC formulation (lower panels). Treatment
with the AC formulation (AC + ODN) induced changes in cell morphology associated with stress ﬁber formation (arrowhead), intercellular
gap formation (G), and the loss of VE-cadherin and ZO-1. (b) Western blot analysis of actin, VE-cadherin, ZO-1, and claudin-5. The whole
cell extract obtained from the cells was separated by SDS-PAGE and immunoblotted with the corresponding antibodies. BC: blank control,
ODN: treated with ODN alone, AC: treated with atelocollagen alone, AC + ODN: treated with the AC formulation.
the impact of the AC formulation on tissue permeability is
associated with the activation of p38 MAP kinase.
4. Discussion
Collagen plays an important role in the extracellular matrix
by supporting cells so that they can form tissues and organs.
Atelocollagen is produced from type I collagen and is widely
usedinitssolidstateasabiomaterialformedicalandsurgical
products because of its biocompatibility and workability [1].
However, the kinetics, dynamics, and biological functions
of atelocollagen after its injection into the living body are
still poorly understood, and it is essential to elucidate the
characteristics of atelocollagen in order to fully exploit its
potential.
Here, we demonstrated a novel biological function of
atelocollagen. When endothelial cell sheets were treated with
atelocollagen or oligonucleotides alone, the intercellular
structure of the sheet was not changed. However, when
the atelocollagen and oligonucleotides were administered
together, intercellular gaps formed and consequently the
paracellular ﬂux of the sheet was elevated. The AC formula-
tion itself was also able to penetrate the sheet. This function
mightexplaintheabilityofatelocollagentoeﬀectivelydeliver
oligonucleotides. The abovementioned changes were elicited
via the activation of p38 MAP kinase, a signal-transduction-
related molecule. In addition, the changes observed in
this study are similar to those triggered by thrombin
[32], histamine [33], TNF-α [34, 36], and VEGF (vascular
endothelial growth factor) [43], and so forth. As shown in
Section 3.1, the degree to which endothelial function was
aﬀected was dependent on the molecular structure of the
oligonucleotides including their size and chemical modiﬁca-
tions, suggesting that the three-dimensional structure of the
oligonucleotide and atelocollagen complex stimulates a sig-
nal transduction pathway that acts as a permeability modu-
lator,althoughthespeciﬁcpathwaythatitstimulatesremains
unknown.
To date, no severe systemic edema or side eﬀects of the
AC formulation have been noted, even after the intravenous
administration of atelocollagen as an oligonucleotide drug
carrier. These ﬁndings indicate that atelocollagen could be
used as a permeability enhancer at local treatment sites
without the adverse systemic eﬀects that cytokines and
chemokines sometimes provoke. Since tight junction mod-
ulators are regarded as practical drug delivery enhancer can-
didates [44–46], the function of atelocollagen demonstrated
in the present study should be thoroughly investigated.Journal of Drug Delivery 7
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Figure 5: Eﬀects of the AC formulation on the microtubule networks in the endothelial cells. Images of α-tubulin (left panels) and α-tubulin
(green) with actin (red) (right panels). In the blank control (upper), the microtubule network was composed of extended ﬁne microtubule
structures. After treatment with the AC formulation (AC + ODN), the ﬁne microtubules had been disassembled, and the network had
disintegrated (lower).
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Figure 6: Eﬀects of the AC formulation on the expression of
signal transduction-related molecules. Western blot analysis of the
expression levels of p38 MAP-kinase, the p42/44 MAP-kinases, and
their phosphorylated forms, RhoA and Cdc42 was performed after
each treatment. BC: blank control, ODN: treated with ODN alone,
AC: treated with atelocollagen alone, AC + ODN: treated with AC
formulation. p38 MAP-kinase activation was only enhanced by the
AC formulation.
The unique biological functions of atelocollagen have
led to the development of unique antitumor therapies
and products, such as surgical products; formulations that
sustain the release of antitumor proteins [2–4]; treatments
that enhance the antitumor activities of various molecules
including antisense ODN [11–13], siRNA [14–20, 24],
and miRNA [21–23]. Obtaining more information about
atelocollagen would allow us to develop the next generation
of atelocollagen-mediated drug delivery systems.
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